
Compounded GLP-1 Sourcing in 2026: Black Mold, Warning Letters, and What the Fifth Circuit Settled
If you prescribe compounded semaglutide or tirzepatide — or you are weighing whether to add them to a cash-pay service line — most of what you'll find online is about price. What most coverage skips is the part that actually puts your license and your patients at risk: where the active ingredient came from, what the FDA is doing about it, and what a federal appeals court just made final.
This guide covers the three enforcement developments that changed the compounded GLP-1 picture in 2026 — the FDA's findings at two Chinese active-ingredient suppliers, the June warning letters over how compounded GLP-1s were labeled and marketed, and the Fifth Circuit's August ruling that closed the shortage loophole — and what each one means for how you verify your supply chain before you write the next prescription.

Quick answer
Compounded semaglutide and tirzepatide are not FDA-approved, and the shortage exception that once let pharmacies mass-produce them is gone. On August 27, 2026, the Fifth Circuit upheld the FDA's decisions removing both drugs from the shortage list. In September and October 2026, the FDA placed two Chinese active-ingredient suppliers on import alert after inspectors reported black mold and quality-control failures. If you prescribe compounded GLP-1s, verify your pharmacy's ingredient source and stop using "FDA-approved" language in your marketing.
What the FDA found at two Chinese API suppliers
In October 2026, Bloomberg reported on FDA inspection reports — obtained through a Freedom of Information Act request — documenting "egregious conditions" at two Chinese factories that make the active ingredients for compounded GLP-1 drugs. The FDA has placed both companies on Import Alert 66-40, "Detention Without Physical Examination of Drugs From Firms Which Have Not Met Drug GMPs" — Chengdu Shengnuo is listed as published September 19, 2026 and Nanjing Chengong October 1, 2026, according to the FDA's import-alert page — meaning their products can be blocked from entering the U.S.
At Chengdu Shengnuo Biopharm, in southwest China, inspectors arriving in August 2026 reported black mold on equipment, "gross contamination" on floors, and "significant insect activity" in the ceilings, according to Bloomberg. Bloomberg also reported that quality-control staff were seen running documents from the lab and stuffing them into lockers — inspectors said they were not able to recover all of the papers — and pouring product samples into sinks.
At Nanjing Chengong Pharmaceutical, on China's east coast, inspectors found in September 2026 that workers had been buying active ingredients made by other factories and then placing Nanjing Chengong's own approval seal on them. According to Bloomberg, staff did not review the other factories' testing information to confirm the products were safe.
Both companies manufactured semaglutide and tirzepatide. Michael Rogers, a principal at Canal Row Advisors and a former associate commissioner for inspections and investigations at the FDA, told Bloomberg the inspection findings "suggest a serious accident waiting to happen."
The import alert is not a recall: shipments can be detained without physical examination, and the importer must document to the FDA that the violations for the affected products have been corrected before they are released. For a prescriber, the message is simpler: you cannot assume the API is clean just because a pharmacy put it in a vial.
Why your pharmacy's supply chain is your problem
Compounded drugs do not go through FDA premarket review the way approved drugs do. As the FDA stated directly in its June 2026 warning letters, compounded drug products "have not been evaluated by FDA for safety, effectiveness, or quality before marketing." The agency's oversight of ingredients is indirect: according to Bloomberg, compounding facilities are required to buy ingredients from FDA-registered manufacturers, and inspectors make spot checks of suppliers. The gaps between checks can be long. Nanjing Chengong was last inspected in March 2025 and Chengdu Shengnuo in September 2023, according to agency records cited by Bloomberg.
The exposure isn't confined to one corner of the market: Bloomberg cites a 2025 Brookings Institution report finding that China supplies a significant proportion of the active ingredients in compounded GLP-1 drugs, and naming Nanjing Hanxin — Nanjing Chengong's parent — as a large supplier.
What this means for you: when you prescribe a compounded GLP-1, you are relying on the compounding pharmacy's sourcing diligence. Ask the pharmacy, in writing, to identify the FDA-registered manufacturer of the API for the specific product you are prescribing, and to confirm that manufacturer is not on an FDA import alert.

The warning letters: labels, "FDA-approved pharmacy," and who the compounder is
On June 8, 2026, the FDA issued warning letters to two companies — HydraMed IV LLC in Denver, Colorado, and Glow Medispa, LLC, doing business as Mint Med — over how they presented compounded semaglutide and tirzepatide on their websites.
Both letters cite a labeling problem. The compounded products pictured on each website identified the company's own name on the label — "HydraMed" or "Mint Med" — "suggesting [the company] is the compounder of those drugs when in fact it is not," in the FDA's words. The FDA held that this made the products misbranded under sections 502(a) and 502(bb) of the FD&C Act, and their introduction into interstate commerce a prohibited act under section 301(a). Each company was given 15 business days to respond.
The HydraMed letter adds a second violation, and it is the one prescribers should notice. HydraMed's website said its compounded products were sourced from an "FDA-approved pharmacy." The FDA's response: compounding facilities, including pharmacies and outsourcing facilities, "are not 'FDA-approved' or 'FDA-licensed' entities," and the Federal Food, Drug, and Cosmetic Act establishes no such designation. The agency treated the claim as false or misleading. (The Mint Med letter cites only the labeling violation.)
The lesson isn't limited to those two firms. "FDA-approved pharmacy" is a category that does not exist, and using it in your own marketing — or repeating it because a telehealth partner used it — is exactly the kind of claim the FDA has now cited in a warning letter. The only accurate statements are narrower: an individual FDA-approved drug (like Ozempic, Wegovy, Mounjaro, or Zepbound) has been approved, but a compounded product and the pharmacy that makes it have not.
What the Fifth Circuit actually settled on August 27, 2026
The shortage exception has been on life support since 2025, but the compounders kept litigating it. That ended on August 27, 2026, when a three-judge panel of the Fifth Circuit — Judges Richman, Duncan, and Oldham — issued two decisions upholding the FDA's removal of both semaglutide and tirzepatide from the drug shortage list.
The timeline behind the ruling, from FDA records: tirzepatide (Mounjaro and Zepbound) was removed from the shortage list on October 2, 2024, a decision the FDA confirmed on December 19, 2024 after a voluntary remand. Semaglutide (Ozempic and Wegovy) was removed on February 21, 2025. The semaglutide enforcement-discretion windows closed shortly after: for 503A pharmacies, the FDA's page says until April 22, 2025 or the district court's decision (April 24, 2025), whichever was later; for 503B outsourcing facilities, May 22, 2025.
The compounders — the Outsourcing Facilities Association and North American Custom Laboratories, doing business as FarmaKeio Superior Custom Compounding — argued under the Administrative Procedure Act that the FDA should have used formal notice-and-comment rulemaking and that its shortage determination was arbitrary and capricious. The panel rejected both. On the procedural point, the semaglutide opinion held that "any error by the FDA in not proceeding through the APA's notice and comment procedures was harmless, and the FDA's ultimate action was not arbitrary or capricious." On the substance, according to Clark Hill, the court held in the tirzepatide case that the FDA reasonably found manufacturer supply data more probative than the screenshots, patient reports, and surveys the compounders offered.
Two caveats matter for how you read this. First, the opinions are not designated for publication (Fifth Circuit Rule 47.5), so they are generally not binding precedent — but as Clark Hill noted in its September 10, 2026 analysis, district courts considering materially similar challenges must apply the same governing standards, which should produce the same result absent materially different facts or a different legal theory. Second, the ruling did not outlaw compounding. It closed the shortage-based pathway. Patient-specific compounding remains on the table, on different terms.
Shortage-based vs. patient-specific compounding: what changed
Question | Shortage era (pre-2025) | After the Fifth Circuit (2026) |
|---|---|---|
Can a pharmacy mass-produce semaglutide/tirzepatide copies? | Yes, while the drug was on the shortage list | No — the shortage exception is gone |
Can a 503B outsourcing facility compound these from bulk API? | Yes, while on the shortage list | No — they're not on the shortage list, and FDA proposed (April 30, 2026) to exclude them from the 503B bulks list |
Can a 503A pharmacy compound for an identified patient? | Yes | Yes, if the statutory conditions are met |
Does adding vitamin B12 make a copy legal? | Not addressed | Not by itself — FDA's policy says semaglutide plus B12 may still be considered "essentially a copy" without a documented patient-specific difference |
Is compounded semaglutide/tirzepatide "FDA-approved"? | Never was | Still is not |
The last two rows are the ones that trip up practices. The FDA's compounding-policy page (updated April 2026) gives semaglutide combined with vitamin B12 as an example of a product that may be considered "essentially a copy" of the approved drug when the amounts are within 10% of the approved strengths — unless a prescriber documents a significant difference for an identified individual patient.

What is still legal to compound
This is where the picture narrows sharply, and where a prescriber's documentation actually matters. Under section 503A, a pharmacy may compound for an identified individual patient based on a prescription, and the FDA says a compounder must not compound "regularly or in inordinate amounts" drug products that are essentially copies of commercially available products. A prescriber who determines — and documents — that a compounded product produces a significant difference for a particular patient (for example, the patient cannot tolerate an inactive ingredient in the approved drug) can satisfy that requirement.
Clark Hill's analysis draws the line: a formulation for one patient who can't tolerate an ingredient "presents a different situation from a program that routinely directs large numbers of patients to substantially the same compounded product." Standardized, program-wide prescribing is what the shortage exception used to cover — and no longer does.
On the 503B side, the FDA proposed on April 30, 2026 to exclude semaglutide, tirzepatide, and liraglutide from the bulks list. Commissioner Marty Makary, M.D., M.P.H., said: "When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need."
Watch for misinformation: "compounded" is not a synonym for "FDA-approved," and "the pharmacy is licensed" is not the same as "the pharmacy is FDA-approved." A licensed state pharmacy can still be compounding a product the FDA has never reviewed for safety, effectiveness, or quality, using an API from a supplier that is on an import alert.
The compliance checklist for prescribers
If you prescribe compounded GLP-1s — or your practice is considering them — work through these before the next prescription:
Confirm, in writing, the identity of the compounding pharmacy and whether it operates under 503A or 503B.
Ask the pharmacy to name the FDA-registered manufacturer of the API for the specific product, and check that manufacturer against the FDA import-alert list.
Remove "FDA-approved," "FDA-licensed," or "FDA-approved pharmacy" from any marketing, website copy, or patient-facing language about compounded products.
Ensure each compounded GLP-1 prescription is tied to an identified patient with a documented clinical reason — not a standardized, program-wide protocol.
If you rely on a "significant difference" (for example, an inactive-ingredient intolerance), document it in the chart for that specific patient.
Ask your health-law counsel whether your state board of pharmacy has issued its own guidance on compounded semaglutide or tirzepatide.
Frequently asked questions
Is compounded semaglutide or tirzepatide FDA-approved?
No. The FDA does not review or approve compounded drugs for safety, effectiveness, or quality before marketing. Only the brand-name products (Ozempic, Wegovy, Mounjaro, Zepbound) are FDA-approved drugs.
Is it still legal to compound GLP-1s in 2026?
Patient-specific compounding under section 503A can be lawful when a prescription is tied to an identified patient and the FDA's limits on "essentially a copy" products are met. What ended is the shortage-based mass production that was legal while the drugs were on the shortage list.
What did the Fifth Circuit decide?
On August 27, 2026, a three-judge panel upheld the FDA's decisions removing semaglutide and tirzepatide from the drug shortage list, rejecting the compounders' arguments that the FDA should have used notice-and-comment rulemaking and that its determination was arbitrary and capricious. Both opinions are unpublished and generally not binding precedent.
Does adding vitamin B12 make a compounded GLP-1 legal?
Not by itself. The FDA's policy gives semaglutide plus vitamin B12 as an example of a product that may still be considered "essentially a copy" of the approved drug, unless a prescriber documents a significant difference for an identified patient.
What is an "FDA-approved pharmacy"?
Nothing — the category does not exist. The FD&C Act does not establish an "FDA-approved" or "FDA-licensed" designation for pharmacies or outsourcing facilities, and the FDA cited this claim in a June 2026 warning letter to HydraMed.
What should I ask my compounding pharmacy?
Ask, in writing, for the identity of the FDA-registered manufacturer of the active ingredient for the specific product you prescribe, and confirm that manufacturer is not on an FDA import alert.
The Bottom Line
Compounded GLP-1s were always a different regulatory product from the approved drugs, but 2026 made that difference costlier to ignore. The shortage exception is gone, two Chinese API suppliers are on an import alert after inspectors reported black mold and quality-control failures, and the FDA has cited an "FDA-approved pharmacy" claim in a warning letter. The prescribers who stay safe are the ones who treat the supply chain as their responsibility — verify the pharmacy, verify the API manufacturer, and drop the "FDA-approved" language entirely.
Ready to add peptides to your practice without the compliance landmines? Start with the free peptide training at https://freepeptidetraining.com/, which covers the sourcing and scope-of-practice fundamentals before you write your first script.
This article is for educational purposes for licensed healthcare professionals and is not legal advice. Scope of practice and compounding rules vary by state; confirm requirements with your licensing board and health-law counsel.
Sources
Black mold, bugs found at Chinese plants making GLP-1 compounding agents — Bloomberg / Seattle Times, October 2026
FDA Warning Letter — HydraMed IV LLC dba HydraMed — U.S. FDA, June 2026
FDA Warning Letter — Glow Medispa, LLC dba Mint Med — U.S. FDA, June 2026
Fifth Circuit Upholds FDA GLP-1 Shortage Decisions — Clark Hill PLC, September 2026
FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize — U.S. FDA
FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List — U.S. FDA, April 2026
Outsourcing Facilities Ass'n v. FDA, No. 25-10600 and No. 25-10758 — U.S. Court of Appeals for the Fifth Circuit, August 2026